Engineered Cell And Exosome Therapy For Pulmonary Vascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$838,490.00
Summary
Diseases affecting the blood vessels in the lungs cause early death and the currently available treatments are not curative. We will take advantage of the latest developments in the understanding of the molecular basis of these diseases to design and test a new treatment approach using cells and cell-derived products as a therapy.
Pulmonary hypertension is a disease affecting the blood vessels in the lungs that causes severe shortness of breath and early death. Genetic mutations are known to cause this disease but the precise link between these mutations and the changes in the lungs are poorly understood. If we could understand this process better, we could design better treatments. This project will look at how the cells in the lungs communicate with each other and how this process is disturbed in pulmonary hypertension.
The Identification Of Thoracic Targets For Prevention And Intervention In Bronchopulmonary Dysplasia
Funder
National Health and Medical Research Council
Funding Amount
$316,449.00
Summary
The persistence of breathing problems from infancy to later life is a complication of premature birth with lifelong consequences. Breathing problems often occur together with lung disease, but prematurity can also affect heart and blood vessel development, and weakness of the main breathing muscle. We will find out how much the heart, lungs and diaphragm contribute to breathing problems in babies; helping us to better predict, diagnose and treat severe breathing problems in babies born preterm.
Lung, Heart And Respiratory Muscle Disease After Preterm Birth
Funder
National Health and Medical Research Council
Funding Amount
$1,328,858.00
Summary
Breathing problems persisting into infancy and later life is an important complication of premature birth with lifelong consequences. Breathing problems often occur together with lung disease, but prematurity can also affect heart and blood vessel development, and weakness of the main breathing muscle (the diaphragm). We will find out how much the heart and diaphragm contribute to breathing problems in babies, and will help us to better predict, diagnose and treat severe breathing problems.
Birth is one of the greatest physiological challenges that we will ever experience and so it is not surprising that it is a period of high risk of death. Despite the risk, our understanding of how infants transition from fetal to newborn life is limited. My research is focused on improving our understanding of how infants make the transition at birth so that we can reduce the risks for these most vulnerable of humans. In particular, I want to improve outcomes for infants born very premature.
Circulatory Biomarkers For Idiopathic Pulmonary Fibrosis: Improving Patient Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$841,625.00
Summary
We are going to find molecules in the blood that would improve the diagnosis and treatment of a lung condition called Idiopathic Pulmonary Fibrosis (IPF). The project brings together well characterized patients from the Australian IPF registry, blood samples we have collected from them and cutting edge technologies to complete this project.
I am a developmental lung physiologist who specialises in understanding the factors regulating normal and abnormal lung development as well as the physiological transformation of the lung into an efficient gas-exchange organ at birth.